Laboratory of Yohan Bossé
"Commit to contribute to national and international research groups, networks, and consortia to study heart and lung diseases."
Dr. Bossé and team members are heavily involved in research collaborations with end-users including respirologists, cardiologists, surgeons, and pathologists. These interactions with health care providers are positively influencing research activities, but also ensure that new genomic knowledge reach practitioners. Dr. Bossé’s laboratory is committed to contribute to national and international research groups, networks, and consortia to study heart and lung diseases.
Local and provincial research collaborations
Groupe de recherche sur les valvulopathies (GRV)
Groupe de recherche en santé respiratoire de l’Université Laval (GESER)
Centre de recherche sur le cancer (CRC)
National and international research collaborations
Canadian Respiratory Research Network
International COPD Genetics Consortium (ICGC)
International Lung Cancer Consortium (ILCCO)
The Merck-Laval-UBC-Groningen Lung eQTL Consortium
Dr. Bossé and colleagues have recently completed the first lung expression quantitative trait loci (eQTL) mapping study [PMID: 23209423]. This study was performed in collaboration with scientists from Merck & Co. Inc. (Rahway, New Jersey, USA), University of British-Columbia (Vancouver), and Groningen University (Groningen, The Netherlands). Briefly, 1,111 human lung specimens obtained from surgery were interrogated using whole-genome gene expression and genotyping microarrays. For each patient, the expression levels of 51,562 transcripts in the lung and the genotype information for 1.2 million single nucleotide polymorphisms (SNPs) were measured. This genomic dataset is now being analyzed in relation with clinical variables such as smoking history, lung function, pathology report, comorbidities, and medication. This study represents an important step in genomics of lung diseases following the completion of large-scale genome-wide association studies (GWAS) on asthma, lung cancer and COPD.
BAVCon is the first international registry of patients with BAV and is planning the most important genetic research projects on BAV. BAVCon includes investigators from 15 sites in the US, Spain, England, Germany, Belgium, Italy, and Canada (http://clinicaltrials.gov/show/NCT01980797).
